That's why nature enthusiasts practice the "leave no trace" philosophy, which encourages those in outdoor spaces to leave ...
MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...
On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback